Caplin Point Laboratories Limited is possibly the only mid-sized company in India’s pharmaceutical sector to be engaged in the R&D and manufacture of finished formulations, APIs, clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. The Company’s unique business model has helped generate the resources to build world-class infrastructure. The Company’s debt-free and cash surplus situation positions it attractively to address the opportunities of the future. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.
One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.
Caplin Point has 4000 + products registrations across the globe with 650 + pharmaceutical formulations & over 36 therapeutic sections.